This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Alemtuzumab is an anti-CD52 monoclonal antibody indicated for the treatment of relapsing-remitting multiple sclerosis (RRMS) with high disease activity despite previous disease-modifying therapies.1 It is administered by IV infusion in a first cycle of 12 mg/d for 5 days (60 mg) and in a second cycle of 12 mg/d for 3 days (36 mg) after 12 months from the first cycle. The most common infusion-associated reaction (IAR), occurring in 90% of alemtuzumab-treated patients, is cytokine-release syndrome, which is managed by premedicating with steroids and treating with symptomatic therapy. Incidence of cardiac-related IARs is 13% (tachycardia, bradycardia, palpitations), of which only 0.7% are serious cardiac-related IARs such as atrial fibrillation, sinus bradycardia, sinus tachycardia, hypotension, or hypertension, and all these events are most frequent on the first day of infusion.2
Footnotes
↵* These authors contributed equally to this work.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 819
See page 827
See page 849
- Received September 17, 2017.
- Accepted in final form January 19, 2018.
- © 2018 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.